[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100312174":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":38,"responsibleParty":55,"collaborators":59,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":12,"enrollmentInfo":80,"targetDuration":12,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":12,"overallStatus":41,"whyStopped":12,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Ludwig-Maximilians - University of Munich","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard care follow-up group","NO_INTERVENTION","Patients will receive an information leaflet (see appendix), which advises on recommended routine follow-up according to international guidelines.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Special care follow-up group","ACTIVE_COMPARATOR","In addition to the information leaflet patients will be actively contacted by the clinical center to increase the likelihood that patients meet recommended follow-up schedules.",[18],"Other: Contact by clinical center",[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":12},"Contact by clinical center","Patients will be acitvely contacted by the clinical center for follow-up procedure",[14],[25],{"name":26,"affiliation":27,"role":28},"Felix Beuschlein, M.D.","University of Zurich","PRINCIPAL_INVESTIGATOR",[30,34],{"name":26,"role":31,"phone":32,"phoneExt":12,"email":33},"CONTACT","+41 44 255 36 25","felix.beuschlein@usz.ch",{"name":35,"role":31,"phone":36,"phoneExt":12,"email":37},"Martin Reincke, M.D.","+49 89 4400 52100","martin.reincke@med.uni-muenchen.de",[39],{"facility":40,"status":41,"city":42,"state":12,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"University Hospital Zurich","RECRUITING","Zurich","8091","Switzerland","CH",{"type":47,"coordinates":48},"Point",[49,50],8.55,47.36667,{"lat":50,"lon":49},[53,54],{"name":26,"role":31,"phone":32,"phoneExt":12,"email":33},{"name":35,"role":31,"phone":36,"phoneExt":12,"email":37},{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"SPONSOR_INVESTIGATOR","Felix Beuschlein","Prof.",[60,62,64,65,67,69],{"name":61,"class":6},"Technische Universität Dresden",{"name":63,"class":6},"Wuerzburg University Hospital",{"name":27,"class":6},{"name":66,"class":6},"Radboud University Medical Center",{"name":68,"class":6},"Lübeck University Clinic",{"name":5,"class":6},"100312174","multicenter-pheochromocytoma-and-paraganglioma-evaluation-100312174",false,"NCT03344016","Multicenter Pheochromocytoma and Paraganglioma Evaluation","The MUPPET-study: Multicenter Pheochromocytoma and Paraganglioma Evaluation for Follow-up Screening, Genetics Sub-Typing, Therapy and Outcome","MUPPET","Inclusion Criteria:\n\nmale and female patients (≥ 5 years of age), who fulfill one or more of the following criteria: (i) Patients with a newly diagnosed PPGL. (ii) Patients with a previous history of PPGLs. (iii) Carrier of genetic mutations known to predispose for the development of PPGLs.\n\nAll subjects must have read, understood and signed the informed consent form, before inclusion into the study protocol. Signed parental consent must be obtained for children with suspected PPGLs who are enrolled in the study.\n\nExclusion Criteria:\n\n* Patients with impaired mental capacity that precludes informed consent.\n* Pregnancy does not constitute criteria for exclusion from the protocol. However, in pregnant women no Clonidine testing, no PET scanning, MIBG scanning or contrast CT will be performed.\n* Patients at risk from injury from the MRI magnet due to implantable metal or who suffer from anxiety in enclosed spaces are excluded from MRI.","ALL","5 Years",{"count":81,"type":82},1148,"ESTIMATED","INTERVENTIONAL",[85],"NA","Target population:\n\nPatients with (1) newly diagnosed or (2) past history of pheochromocytomas and paragangliomas (PPGL) or (3) carrier of genetic mutations in known PPGL susceptibility genes.\n\nInternational multicenter prospective cohort study with randomized intervention (special care follow-up vs. standard care follow-up).\n\nAll patients will receive instructions about follow-up at the time point of study inclusion. Patients randomized to the standard care follow-up group will be advised to return annually for follow-up according to current routine practice (without active re-scheduling). In contrast, patients randomized to the special care follow-up group will also be advised to return annually for follow-up but these patients will be actively invited, re-scheduled and reminded by the centers to meet scheduled follow-up appointments.",[88,89],"Pheochromocytoma","Paraganglioma","2020-07-07",{"date":92,"type":93},"2020-07-09","ACTUAL",{"date":95,"type":93},"2017-11-01",{"date":97,"type":82},"2040-11-01",{"name":57,"class":6},1]